The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending Approval Of Merck's Keytruda In Combination With Padcev (Enfortumab Vedotin) For The First-line Treatment Of Unresectable Or Metastatic
The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending Approval Of Merck's Keytruda In Combination With Padcev (Enfortumab Vedotin) For The First-line Treatment Of Unresectable Or Metastatic
歐洲藥品管理局人用藥品委員會通過了對默沙東的Keytruda聯合Padcev (Enfortumab Vedotin)作爲不可手術或轉移性的一線治療的正面意見建議。
The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending Approval Of Merck's Keytruda In Combination With Padcev (Enfortumab Vedotin) For The First-line Treatment Of Unresectable Or Metastatic
歐洲藥品管理局人用藥品委員會通過了對默沙東的Keytruda聯合Padcev (Enfortumab Vedotin)作爲不可手術或轉移性的一線治療的正面意見建議。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。